Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 2, 2008, Pages 175-180

  Yang, Yun Liang ^a   Wang, An Huei ^b   Wang, Chih Wei ^b   Cheng, Wei Ting ^b   Li, Shu Ying ^c   Lo, Hsiu Jung ^b  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

Candida; Resistance; Susceptibility

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TAIWAN;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; TAIWAN;

EID: 43749123271     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.01.011     Document Type: Article

References (42)

1. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., and Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24 (1997) 1122-1128
2. Akova M., Akalin H.E., Uzun O., and Gur D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 598-599
3. Arthington-Skaggs B.A., Lee-Yang W., Ciblak M.A., Frade J.P., Brandt M.E., Hajjeh R.A., Harrison L.H., Sofair A.N., and Warnock D.W. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob. Agents Chemother. 46 (2002) 2477-2481
4. Barchiesi F., Calabrese D., Sanglard D., Falconi D.F., Caselli F., Giannini D., Giacometti A., Gavaudan S., and Scalise G. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob. Agents Chemother. 44 (2000) 1578-1584
5. Calvet H.M., Yeaman M.R., and Filler S.G. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41 (1997) 535-539
6. Chen Y.C., Chang S.C., Sun C.C., Yang L.S., Hsieh W.C., and Luh K.T. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect. Control Hosp. Epidemiol. 18 (1997) 369-375
7. Cheng M.F., Yu K.W., Tang R.B., Fan Y.H., Yang Y.L., Hsieh K.S., Ho M., and Lo H.J. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis. 48 (2004) 33-37
8. Chou H.H., Lo H.J., Chen K.W., Liao M.H., and Li S.Y. Multilocus sequence typing of Candida tropicalis shows clonal cluster enriched in isolates with resistance or trailing growth of fluconazole. Diagn. Microbiol. Infect. Dis. 58 (2007) 427-433
9. Clinical and Laboratory Standards Institute (formally NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard (1997), CLSI, M27A. Wayne, PA
10. Fleck R., Dietz A., and Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J. Antimicrob. Chemother. 59 (2007) 767-771
11. Hadfield T.L., Smith M.B., Winn R.E., Rinaldi M.G., and Guerra C. Mycoses caused by Candida lusitaniae. Rev. Infect. Dis. 9 (1987) 1006-1012
12. Hung C.C., Chen Y.C., Chang S.C., Luh K.T., and Hsieh W.C. Nosocomial candidemia in a university hospital in Taiwan. J. Formos. Med. Assoc. 95 (1996) 19-28
13. Hung C.C., Yang Y.L., Lauderdale T.L., McDonald L.C., Hsiao C.F., Cheng H.H., Ho Y.A., and Lo H.J. Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida species. J. Clin. Microbiol. 43 (2005) 1600-1603
14. Kontoyiannis D.P. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis. 34 (2002) 1281-1283
15. Leaw S.N., Chang H.C., Sun H.F., Barton R., Bouchara J.P., and Chang T.C. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol. 44 (2006) 693-699
16. Leaw S.N., Chang H.C., Barton R., Bouchara J.P., and Chang T.C. Identification of medically important Candida and non-Candida yeast species by an oligonucleotide array. J Clin Microbiol. 45 (2007) 2220-2229
17. Lee M.K., Williams L.E., Warnock D.W., and Arthington-Skaggs B.A. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob. Chemother. 53 (2004) 217-224
18. Lo H.J., Ho A.H., and Ho M. Factors accounting for mis-identification of Candida species. J Microbiol Immunol Infect 34 (2001) 171-177
19. Lo H.J., Cheng H.H., and TSARY Hospitals. Distribution of clinical yeasts in Taiwan. Fung. Sci. 20 (2005) 83-91
20. Marr K.A., Lyons C.N., Ha K., Rustad T.R., and White T.C. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother. 45 (2001) 52-59
21. Orozco A.S., Higginbotham L.M., Hitchcock C.A., Parkinson T., Falconer D., Ibrahim A.S., Ghannoum M.A., and Filler S.G. Mechanism of fluconazole resistance in Candida krusei. Antimicrob. Agents Chemother. 42 (1998) 2645-2649
22. Peman J., Canton E., and Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 24 (2005) 23-30
23. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., Doern G.V., Brandt M.E., and Hajjeh R.A. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. 33 (1999) 217-222
24. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Messer S.A., Houston A., Coffman S., and Hollis R.J. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44 (2000) 747-751
25. Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., and Hollis R.J. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J. Clin. Microbiol. 41 (2003) 1440-1446
26. Pfaller M.A., Messer S.A., Boyken L., Hollis R.J., Rice C., Tendolkar S., and Diekema D.J. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48 (2004) 201-205
27. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46 (2007) 150-156
28. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Meis J.F., Gould I.M., Fu W., Colombo A.L., and Rodriguez-Noriega E. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45 (2007) 1735-1745
29. Prasad K.N., Agarwal J., Dixit A.K., Tiwari D.P., Dhole T.N., and Ayyagari A. Role of yeasts as nosocomial pathogens and their susceptibility to fluconazole and amphotericin B. Indian J Med. Res. 110 (1999) 11-17
30. Slavin M.A., Osborne B., Adams R., Levenstein M.J., Schoch H.G., Feldman A.R., Meyers J.D., and Bowden R.A. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J. Infect. Dis. 171 (1995) 1545-1552
31. St Germain G., Laverdiere M., Pelletier R., Bourgault A.M., Libman M., Lemieux C., and Noel G. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin. Microbiol 39 (2001) 949-953
32. Walsh T.J., Hiemenz J.W., Seibel N.L., Perfect J.R., Horwith G., Lee L., Silber J.L., DiNubile M.J., Reboli A., Bow E., Lister J., and Anaissie E.J. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26 (1998) 1383-1396
33. Walsh T.J., Groll A., Hiemenz J., Fleming R., Roilides E., and Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10 Suppl 1 (2004) 48-66
34. Wang J.S., Li S.Y., Yang Y.L., Chou H.H., and Lo H.J. Association between fluconazole susceptibility and genetic relatedness among Candida tropicalis isolates in Taiwan. J Med. Microbiol. 56 (2007) 650-653
35. White T.C., Marr K.A., and Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11 (1998) 382-402
36. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39 (2004) 309-317
37. Yang Y.L., and Lo H.J. Mechanisms of antifungal agent resistance. J Microbiol Immunol Infect 34 (2001) 79-86
38. Yang Y.L., Cheng H.H., and Lo H.J. In vitro activity of voriconazole against Candida species isolated in Taiwan. Int. J. Antimicrob. Agents 24 (2004) 294-296
39. Yang Y.L., Ho Y.A., Cheng H.H., Ho M., and Lo H.J. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp. Epidemiol. 25 (2004) 60-64
40. Yang Y.L., Ho Y.A., Cheng H.H., and Lo H.J. Distribution and susceptibility to amphotericin B and fluconazole of Candida spp. isolated from Taiwan. Epidemiol Infect 133 (2005) 325-330
41. Yang Y.L., Li S.Y., Cheng H.H., and Lo H.J. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn. Microbiol. Infect. Dis. 51 (2005) 179-183
42. Yang Y.L., Cheng H.H., and Lo H.J. Distribution and antifungal susceptibility of Candida species isolated from different age populations in Taiwan. Med. Mycol. 44 (2006) 237-242